Targeting the Hedgehog pathway in cancer: can the spines be smoothened?

Clinical cancer research : an official journal of the American Association for Cancer Research ·Vol. 17 ·No. 8 ·2011-04-15 ·Pages 2071-3

Ailles L, Siu LL

Abstract

Aberrant Hedgehog (Hh) pathway signaling has been suggested to play a role in the development of multiple solid tumors and hematologic malignancies. GDC-0449 is a novel first-in-human, first-in-class smoothened (SMO) inhibitor, which has completed its phase I evaluation and achieved proof of concept in tumors with Hh pathway mutations.

MeSH Terms

Anilides/metabolism,pharmacokinetics,therapeutic use Dose-Response Relationship, Drug Gene Expression Regulation, Neoplastic/drug effects Hedgehog Proteins/antagonists & inhibitors,metabolism Humans Metabolic Clearance Rate Neoplasm Metastasis Neoplasms/drug therapy,metabolism,pathology Orosomucoid/metabolism Protein Binding Pyridines/metabolism,pharmacokinetics,therapeutic use Signal Transduction/drug effects Transcription Factors/genetics Treatment Outcome Zinc Finger Protein GLI1

Chemicals

Anilides GLI1 protein, human Hedgehog Proteins HhAntag691 Orosomucoid Pyridines Transcription Factors Zinc Finger Protein GLI1

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Ailles Laurie

Princess Margaret Hospital, Ontario Cancer Institute, University of Toronto, Toronto, Canada.

Siu Lillian L

Article Info

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Abbr.

Clin Cancer Res

ISSN

1557-3265

DOI

10.1158/1078-0432.CCR-11-0211

Published

2011-04-15

Epub

2011-00-02

Pages

2071-3

Language

English

Region

United States

NLM ID

9502500

Subset

Corrections

CommentOn

PMID: 21300760

CommentOn

PMID: 21300762

External Links

PubMed source DOI: 10.1158/1078-0432.CCR-11-0211 View journal details

Analysis Services

Targeting the Hedgehog pathway in cancer: can the spines be smoothened?

Contact

WeChat Official Account